Pregled bibliografske jedinice broj: 1033882
Single institution experience in fertility preservation in female patients diagnosed with early stage cancer
Single institution experience in fertility preservation in female patients diagnosed with early stage cancer // Libri oncologici
Varaždin, Hrvatska, 2017. str. 62-62 (poster, domaća recenzija, sažetak, ostalo)
CROSBI ID: 1033882 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Single institution experience in fertility
preservation in female patients diagnosed with
early stage cancer
Autori
Iva Marinčić, Petra Vuković, Jelena Raguž, Nikolina Vincelj, Robert Šeparović
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Libri oncologici
/ - , 2017, 62-62
Skup
9th Symposium and Annual Meeting of Croatian Society for Medical Oncology of Croatian Medical Association with International Participation and 11th Meeting of Oncology Pharmacy Section of Croatian Pharmaceutical Society with International Participation
Mjesto i datum
Varaždin, Hrvatska, 20.10.2017. - 22.10.2017
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
hrčak, hrcak, znanstveni časopisi, hrvatski, scientific journals, croatian
Sažetak
This is the review of our experience in fertility preservation in female patients diagnosed with early stage cancer. The aim of the review was to show, whether cryopreservation prolonges time until chemotherapy. A retrospecitve study was conducted from March 2015 to March 2017 at the Department of Medical Oncology University Hospital for Tumors, Sestre milosrdnice University Hospital Center. Data were collected from medical history. Out of all female patients which were diagnosed with early stage cancer 40 of them wanted to preserve their fertility. Out of total number 38 patents were diagnosed with early stage breast cancer, and two patients were diagosed with colorectal cancer. Patients were between 25 and 43 (median 34) years of age, and they were treated in adjuvant or neoadjuvant sett ing. All patients were off ered with cryopreservation of oocytes or embryos with subcutaneous application of LHRH agonist, or just LHRH agonist application before the start of chemotherapy application or endocrine therapy. Out of 40 patients nine underwent cryopreservation process. Others opted for monthly subcutaneous LHRH agonist application which was conducted during the whole time of chemotherapy application/ endocrine therapy and continued up to three month after last chemotherapy application. Medical record analysis showed that average time from patients presentation at Multdisciplinary team to the fi rst application of chemotherapy was 40.2 days in group that underwent oocyte/embryo cryopreservation, and average time for LHRH group was 21.6 days. Final data of this review is consistent with data available in current literature.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus